Targeted Medical
Targeted Medical Pharma, Inc., a specialty pharmaceutical company, doing business as Physician Therapeutics, develops and commercializes amino acid based medications to physicians, pharmacies, and patients in the United States. It offers a line of patented amino acid based medical food products, dietary supplements, and generic drugs primarily for the treatment of metabolic syndrome/obesity; slee… Read more
Targeted Medical (TRGM) - Net Assets
Latest net assets as of December 2015: $-12.92 Million USD
Based on the latest financial reports, Targeted Medical (TRGM) has net assets worth $-12.92 Million USD as of December 2015.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.43 Million) and total liabilities ($15.35 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-12.92 Million |
| % of Total Assets | -532.27% |
| Annual Growth Rate | N/A |
| 5-Year Change | -2226.8% |
| 10-Year Change | N/A |
| Growth Volatility | 180.81 |
Targeted Medical - Net Assets Trend (2008–2015)
This chart illustrates how Targeted Medical's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Targeted Medical (2008–2015)
The table below shows the annual net assets of Targeted Medical from 2008 to 2015.
| Year | Net Assets | Change |
|---|---|---|
| 2015-12-31 | $-12.92 Million | -29.56% |
| 2014-12-31 | $-9.97 Million | -42.09% |
| 2013-12-31 | $-7.02 Million | -250.53% |
| 2012-12-31 | $-2.00 Million | -429.59% |
| 2011-12-31 | $607.43K | -79.04% |
| 2010-12-31 | $2.90 Million | -73.54% |
| 2009-12-31 | $10.95 Million | +57.71% |
| 2008-12-31 | $6.94 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Targeted Medical's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 869.2% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2015)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $27.73K | % |
| Other Components | $17.04 Million | % |
| Total Equity | $-12.90 Million | 100.00% |
Targeted Medical Competitors by Market Cap
The table below lists competitors of Targeted Medical ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tandem Group
LSE:TND
|
$1.16K |
|
NVPCF
OTCQB:NVPCF
|
$1.16K |
|
Pak Elektron Ltd
KAR:PAEL
|
$1.16K |
|
Sitara Peroxide Ltd
KAR:SPL
|
$1.16K |
|
Renuka Holdings PLC
CM:RHLN0000
|
$1.16K |
|
Tien Son Thanh Hoa JSC
VN:AAT
|
$1.16K |
|
IHUNT TECHNOLOGY IMPORT-EXPORT S.A.
RO:HUNT
|
$1.16K |
|
El Nasr Clothes & Textiles (Kabo)
EGX:KABO
|
$1.16K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Targeted Medical's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2014 to 2015, total equity changed from -9,971,574 to -12,895,489, a change of -2,923,915.
- Net loss of 3,043,810 reduced equity.
- Other factors increased equity by 119,895.
Equity Change Factors (2014 to 2015)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.04 Million | -23.6% |
| Other Changes | $119.89K | +0.93% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Targeted Medical's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | $0.32 | $0.00 | x |
| 2009-12-31 | $0.50 | $0.00 | x |
| 2010-12-31 | $0.13 | $0.00 | x |
| 2011-12-31 | $0.03 | $0.00 | x |
| 2012-12-31 | $-0.09 | $0.00 | x |
| 2013-12-31 | $-0.29 | $0.00 | x |
| 2014-12-31 | $-0.38 | $0.00 | x |
| 2015-12-31 | $-0.47 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Targeted Medical utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -57.86%
- • Asset Turnover: 2.17x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-61.29%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 48.86% | 27.90% | 1.15x | 1.52x | $2.70 Million |
| 2009 | 36.37% | 32.65% | 0.75x | 1.48x | $2.89 Million |
| 2010 | 112.12% | 42.63% | 1.30x | 2.02x | $2.96 Million |
| 2011 | -687.66% | -47.41% | 0.98x | 14.78x | $-4.24 Million |
| 2012 | 0.00% | -131.38% | 0.69x | 0.00x | $-9.39 Million |
| 2013 | 0.00% | -97.72% | 1.91x | 0.00x | $-8.64 Million |
| 2014 | 0.00% | -54.76% | 2.84x | 0.00x | $-2.90 Million |
| 2015 | 0.00% | -57.86% | 2.17x | 0.00x | $-1.75 Million |
Industry Comparison
This section compares Targeted Medical's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Targeted Medical (TRGM) | $-12.92 Million | 48.86% | N/A | $1.16K |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |